BECAUSE angina pectoris is a consequence of inadequate myocardial oxygenation, ideal therapy for this incapacitating symptom would be directed toward both increasing coronary blood flow and decreasing ...
Patients who have received at least one COVID-19 vaccine dose after acute coronary syndromes do not have a reduced risk for cardiovascular events, according to a research letter published online May ...
IN our inquiries into any particular subject of Medicine, our labours will generally be shortened and directed to their proper objects, by a knowledge of preceding discoveries. When Dr. Heberden, in ...
A randomized trial comparing an intensive to a standard diagnostic approach showed the suspected etiology, in cases of MI with nonobstructive coronary arteries, is often wrong.
The goal of the trial was to evaluate a strategy of percutaneous coronary intervention (PCI) plus medical therapy compared with medical therapy alone in patients with low-risk stable coronary artery ...
A drug used in the clinical treatment of angina symptoms also has an anti-inflammatory effect and reduces atherosclerotic plaques in blood vessels -- thereby reducing the risk of heart attack or ...
When a robust man suddenly drops dead and the newspapers report “heart failure,” the probability is that he died during an attack of angina pectoris. If he had gone to his doctor the day before, the ...
A drug used in the clinical treatment of angina symptoms also has an anti-inflammatory effect and reduces atherosclerotic plaques in blood vessels - thereby reducing the risk of heart attack or stroke ...
Between July 2007 and March 2009, A total of 199 consecutive patients (age 71±11 years, 138 men) with ACS (n=79), defined as an acute ST- or non-ST-segment elevation myocardial infarction or Braunwald ...
The diagnosed prevalent cases of angina pectoris is expected to increase from 19.58 million cases in 2018 to 22.79 million cases in 2028, at an annual growth rate (AGR) of 1.64% across the seven major ...
Patients who have received at least one COVID-19 vaccine dose after acute coronary syndromes do not have a reduced risk for cardiovascular events, according to a research letter published online May ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback